EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome

Iris T Lee iD, Daniel E Soffer, Alan T Remaley, Martin P Playford, Nehal N Mehta, Christos Coutifaris, Richard S Legro, Anuja Dokras

European Journal of Endocrinology · 03.08.2026 · 195 (2) · 302-311

DOI: 10.1093/ejendo/lvag149 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Endocrinology, online erschienen am 13.08.2026. Verfasst von Iris T Lee und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, United States. Hauptthemen laut MEDLINE: Polycystic Ovary Syndrome, Metformin, Hypoglycemic Agents, Lipids. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Eunice Kennedy Shriver National Institute of Child Health and Human Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Combined oral contraceptives (OCPs) and metformin are commonly used in patients with polycystic ovary syndrome (PCOS), who are at elevated risk of dyslipidemia and cardiovascular disease (CVD), but their effects on advanced lipid phenotyping remain unclear.

Objective

To examine the impact of OCPs and metformin on (1) lipoproteins, (2) apolipoproteins, and (3) cholesterol efflux capacity (CEC, marker of HDL function).

Design

Secondary analysis of the COMET-PCOS randomized clinical trial.

Setting

Two tertiary care reproductive endocrinology clinics. Patients or Other Participants Patients with hyperandrogenic PCOS and elevated BMI with paired serum samples for lipoprotein/apolipoprotein analysis (n = 180) and cholesterol efflux capacity (n = 129). Intervention(s) 24 weeks of metformin, OCP, or OCP + metformin. Main Outcome Measure(s) Change in HDL particles (HDL-P), low-density lipoprotein particles (LDL-P), triglyceride-rich lipoprotein particles (TRL-P); apolipoproteins A-I, B, and C-III; and CEC.

Results

HDL-P concentration increased in the OCP and OCP + metformin arms, while atherogenic small LDL-P increased slightly. Metformin had a largely neutral effect on advanced lipid phenotyping. Cholesterol efflux capacity increased in the OCP arm, though this was attenuated when adjusting for change in ApoA-I (adjusted ratio of geometric means 1.08, 95% CI 0.99-1.17), which increased in all arms.

Conclusions

In patients with PCOS and high metabolic risk, OCP use resulted in improved HDL-C function and a mixed effect on lipoproteins and apolipoproteins, with no clear benefit from metformin. These findings do not support or refute the cardiovascular risk-benefit of OCP use in PCOS and highlight the need for studies evaluating long-term clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Ovary SyndromeMetforminHypoglycemic AgentsLipidsContraceptives, OralContraceptives, Oral, CombinedHumansFemaleAdultPhenotypeYoung AdultApolipoproteinsLipoproteinsCholesterol

Stichwörter der Autor:innen

apolipoproteincholesterol efflux capacitylipoproteinmetforminoral contraceptive pillspolycystic ovary syndrome

Substanzen

MetforminHypoglycemic AgentsLipidsApolipoproteinsContraceptives, OralContraceptives, Oral, CombinedLipoproteinsCholesterol

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, University of Pennsylvania, Philadelphia, PA 19104, United States.
  • Division of Translational Medicine and Human Genetics, University of Pennsylvania, Philadelphia, PA 19104, United States.
  • National Heart, Lung, and Blood Institute, Bethesda, MD 20892, United States.
  • George Washington University School of Medicine and Health Sciences, Washington, District of Columbia 20037, United States.
  • Department of Obstetrics and Gynecology, M.S. Hershey Medical Center, Hershey, PA 17033, United States.

ORCID-Profile: Iris T Lee

Förderung

  • Eunice Kennedy Shriver National Institute of Child Health and Human Development

Zitieren

APA

Lee, I. T., Soffer, D. E., Remaley, A. T., Playford, M. P., Mehta, N. N., Coutifaris, C., Legro, R. S., & Dokras, A. (2026). Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome. European Journal of Endocrinology, 195(2), 302-311. https://doi.org/10.1093/ejendo/lvag149

Vancouver

Lee IT, Soffer DE, Remaley AT, Playford MP, Mehta NN, Coutifaris C, et al. Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome. European Journal of Endocrinology. 2026;195(2):302-311. doi:10.1093/ejendo/lvag149

BibTeX
@article{Lee2026,
  author = {Lee, Iris T and Soffer, Daniel E and Remaley, Alan T and Playford, Martin P and Mehta, Nehal N and Coutifaris, Christos and Legro, Richard S and Dokras, Anuja},
  title = {Impact of oral contraceptives and metformin on advanced lipid phenotyping in polycystic ovary syndrome},
  journal = {European Journal of Endocrinology},
  year = {2026},
  volume = {195},
  number = {2},
  pages = {302--311},
  doi = {10.1093/ejendo/lvag149}
}
Kostenlos starten →